Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
| Condition | Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma |
|---|---|
| Phase | Phase 2 |
| Sponsor | HonorHealth Research Institute |
| Status | Completed |
| Enrollment | 19 participants |
| Interventions | Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine |
| Start date | Dec 1, 2020 |
| Completion date | Feb 21, 2024 |
| Results posted | Jul 21, 2026 |
Summary
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
CA 19-9 Normalization
| Treatment | 9.1 Percentage of participants |
|---|---|
| Treatment | 18.2 Percentage of participants |
| Treatment | 72.7 Percentage of participants |
| Treatment | 36.4 Percentage of participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group